Zucapsaicin
| Clinical data | |
|---|---|
| Trade names | Civanex | 
| Other names | Civamide; (Z)-Capsaicin; cis-Capsaicin | 
| Routes of administration | Topical | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.527 | 
| Chemical and physical data | |
| Formula | C18H27NO3 | 
| Molar mass | 305.418 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Zucapsaicin (Civanex) is a medication used to treat osteoarthritis of the knee and other neuropathic pain. Zucapsaicin is a member of phenols and a member of methoxybenzenes. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1 that reduces pain, and improves articular functions. It is the cis-isomer of capsaicin. Civamide, manufactured by Winston Pharmaceuticals, is produced in formulations for oral, nasal, and topical use (patch and cream).
Zucapsaicin has been tested for treatment of a variety of conditions associated with ongoing nerve pain. This includes herpes simplex infections; cluster headaches and migraine; and knee osteoarthritis. It was approved by the Health Canada in 2010 as topical cream sold under the brand name Zuacta. It has a melting point of 71.5–74.5 °C.